For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  Tesamorelin
Weight & Metabolicapproved

Tesamorelin

Egrifta
Weight & Metabolic · CAS 218949-48-5
ASK VERA ABOUT THIS ↗BUY NOW ↗
Category
Weight & Metabolic
Evidence grade
A
PubMed records
103
Female-tagged
32
Sex-analysis
1
CAS
218949-48-5
A
Evidence grade A, Approved indication with 32 indexed studies that included female subjects. How grades work →
Female evidence: Direct
Tesamorelin: of 103 PubMed records, 32 are tagged as including female subjects and 1 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-17. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

Tesamorelin is a synthetic, stabilized analog of growth-hormone-releasing hormone (GHRH), carrying an added trans-3-hexenoyl group that improves its stability, and it is used as a tool compound in endocrine and metabolic research. It is an approved medicine studied for the reduction of visceral fat in HIV-associated lipodystrophy.

In vitro and in preclinical systems, tesamorelin has been studied for its activation of the GHRH receptor on pituitary cells, its regulation of the somatotropic axis, and its modeled influence on lipid-metabolism and visceral-adipose pathways. Investigators examining growth-hormone secretion and adipose biology have used it as a research material to probe how increased pulsatile growth-hormone release affects downstream metabolism.

What makes tesamorelin a notable catalog entry is its stabilized GHRH design paired with a defined metabolic research focus. Whether these mechanisms translate to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women.

Summary

Tesamorelin is a growth-hormone-releasing hormone analog approved to reduce visceral fat in HIV-associated lipodystrophy. Its trials included women, and notably suggested a smaller response in women than men, a rare example of a reported sex difference.

Evidence in women

Menstrual cycle
Unstudied
No menstrual cycle interaction data.
Pregnancy & lactation
Contraindicated
Contraindicated in pregnancy per label. Effects in lactation are not established.
Hormonal interactions
No evidence
No clinically significant interaction with contraceptives was characterized in the approval data; estrogen status can influence the GH axis generally.
Perimenopause & menopause
No evidence
Not specifically studied by menopausal status.
Sex differences
Evidence
In HIV-lipodystrophy trials, women appeared to have a smaller reduction in visceral fat than men, one of the few compounds here where a sex difference in response was actually reported, though the female subgroup was small.

Mechanism

A stabilized GHRH analog that binds the GHRH receptor on pituitary cells to increase pulsatile growth-hormone release, which in turn influences visceral adipose tissue.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)Per approved label. Reported here for reference, not as advice.
Routessubcutaneous
Female-specific dosingNot established

Contraindications: pregnancy; active malignancy; disruption of the hypothalamic-pituitary axis

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

injection-site reactionsjoint painfluid retentionincreased blood glucose

Tesamorelin reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for Tesamorelin

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from Tesamorelin's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is Tesamorelin?

Tesamorelin, also known as Egrifta, is a research compound in our weight metabolic category. Tesamorelin is a growth-hormone-releasing hormone analog approved to reduce visceral fat in HIV-associated lipodystrophy.

Is Tesamorelin studied in women?

Tesamorelin: of 103 PubMed records, 32 are tagged as including female subjects and 1 carry a sex-analysis tag. We grade this direct female evidence: at least one record carries a sex-analysis tag, so some findings are drawn from women rather than borrowed from mixed or male data. See how we read the evidence.

Has Tesamorelin been studied during pregnancy or breastfeeding?

Contraindicated. Contraindicated in pregnancy per label. Effects in lactation are not established. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does Tesamorelin have, and why?

Tesamorelin carries evidence grade A. Approved indication with 32 indexed studies that included female subjects.. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for Tesamorelin?

No. A female-specific dose for Tesamorelin is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is Tesamorelin administered in research?

In the published literature, Tesamorelin is administered via subcutaneous. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for Tesamorelin?

Effects reported in the research literature include injection-site reactions, joint pain, fluid retention, increased blood glucose. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

What is the CAS number for Tesamorelin?

The CAS registry number for Tesamorelin is 218949-48-5. It is also referred to as Egrifta, TH9507. Use it to confirm identity against a Certificate of Analysis.

How should Tesamorelin be stored and handled?

Tesamorelin sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy Tesamorelin for research?

For laboratory research use, Tesamorelin is available from our research-use partner, Aurevena Research. Applying code research15 takes 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Buy Tesamorelin at Aurevena Research
Research-use supplier: Tesamorelin is available from our research-use vendor for laboratory use. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Buy now →

Citations (PMID)

17595638 · 20881580

Related peptides

4X Blend (Methionine / Choline / Carnitine / Dexpanthenol)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
5-Amino-1MQD
5-Amino-1MQ: of 3 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.
8X Blend (L-Carnitine / L-Arginine / Methionine / Inositol / Choline / B6 / B5 / B12)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
AdipotideD
Adipotide: of 4 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.